Lyme Disease and
Multiple systemic infection disease syndrome (MSIDS)
Hidden epidemics of dangerous diseases:
The Townsend Letter for Doctors describes these diseases as the fastest spreading infectious diseases in the world.
Our research has provided a breakthrough in the diagnosis and treatment of the diseases through the recognition of the changing phenotypes of Borrelia burgdorferi and its co-infections. This requires daily testing and treatment of resonant frequencies by special equipment currently seeking approval.
This is the Lyme rash which is seen in only 50% of cases (Erythema Migrans).
It is necessary to test and treat Borellia burgdorferi, the primary infection in Lyme Disease
and co-infections causing Multiple Systemic Infection Disease Syndrome (MSIDS), associated with Lyme Disease.
These infections are carried by Ticks and other insects and can transfer to other members of the family.
These infections have been found in breast milk and has also been shown to pass through the placenta.
If you have Lyme Disease when you give birth it is very possible that your child may have become infected.
If you are concerned about any member of your family, we will be happy to provide them with a complimentary Lyme Disease evaluation.
Try our free Lyme questionnaire: Click here: Questionnaire
Make an appointment for a free consultation by telephoning 03 9300 4094.
Lyme disease is caused by a tick borne spirochetal bacteria, Borrelia burgdorferi, which can progress from a characteristic skin rash (erythema migrams EM), to a wide variety of non-specific systemic symptoms that can affect any part of the body.
It is a serious disease that can cause the patient to be confined to a wheel chair and/or die.
Electronic testing produces a graph of the resonant frequencies as shown below:
The pink arrow shows the peak that corresponds to Borellia burgdorferi the primary infection involved in Lyme Disease. The research searches for all resonant frequencies in the patient including the co-infections involved in MSIDS and treats each of these frequencies on a daily basis.
The resonant frequency for Borellia burgdorferi can vary. In this example it is 381,000Hz which is shown on the left side of the yellow bar under the graph. With daily testing of resonant frequencies changes in phenotypes with changes in resonant frequencies are included in the treatment program.
Some of the other peaks represent the resonant frequencies of the co-infections in Lyme Disease which Dr Horowiitz describes as MSIDS.
Electronic testing and treatment, can perform both of these tasks and produce a superior diagnostic result compared to traditional pathology testing and a more effective treatment result compared to antibiotics in the chronic phase of Lyme Disease.
Antibiotics are usually effective only in the first six weeks of Lyme Infections. As only half the patients with Lyme Disease realise they have been infected, the other half are often diagnosed outside the critical six week period.
This electronic approach is very cost effective compared with the cost of multiple medical consultations, multiple pathology tests and multiple treatment modalities.
Many patients struggle with debilitating pain and unending insomnia, symptoms that leave them barely able to work and to deal competently with daily life. However Holt Radiowave Therapy has been very effective in treating this pain.
They see specialists in internal medicine, orthopedics, ophthalmology, psychiatry, and neurology, but still have no definite diagnosis of their frightening symptoms.
Dr Richard Horowitz has led the diagnosis and treatment of Lyme Disease over twenty years in the USA and has recently published an excellent text: 'Why can't I get better?'
'His work provides hope which is a central human emotion, misunderstood and often mistaken for optimism, it is not about holding a rosy and unrealistic prospect for the future. It is not 'Just think positive.' Rather hope is clear eyed. True hope is seeing a viable route out of the darkness while acknowledging the obstacles that might impede your journey.'
Appropriate and early antibiotic treatment within the first six weeks can usually treat the infections.
However in some people a tick bite can lead to a disseminated infection and to disabling physical, cognitive, and psychological manifestation.
And some people manifest with puzzling multiple systemic symptoms that can occur throughout the body, which lead to complex lab results.
Lyme sufferers face difficulty in obtaining appropriate care from often skeptical medical and insurance communities.
One camp, the Infectious Diseases Society of America (IDSA) believes that Lyme disease is an easily diagnosable and treatable condition.
The other camp, the International Lyme and Associated Diseases Society (ILADS), believes that the blood tests to diagnose Lyme Disease are highly unreliable and that thirty days of antibiotics is often insufficient.
A patient's journey typically begins with a primary care physician or a family doctor.If patients report back that they are not getting better after thirty days of antibiotics, they are likely to be diagnosed as having "post-Lyme syndrome, chronic fatigue syndrome (CFS, which is now often referred to as myalgic encephalomyelitis), or fibromyalgia."
They are then given an antidepressant and/or the number of a local psychiatrist, or told to live with their symptoms.
When a child contracts Lyme Disease and can't concentrate in school and/or shows a decline in their grades and attention span, then the child must have Attention Deficit Disorder (ADD), or perhaps there are problems at home. They are typically given Ritalin, or Strattera, and sent for behavioral therapy. This may help some of the symptoms yet fail to address the root problem.
Please watch this important video:
This bull's eye lesion is seen after a tick bite in only 50% of patients.
View Dr Luc Montagier, Nobel Prize 2008, discussing the urgent need for prevention:
Telephone 03 9300 4094 to arrange a free electronic test for these diseases and complete the
Application for treatment on the Internet.
The hypothesis that Borrelia and the co-infections can change their phenotype and thus their resonant frequency is supported by this recent melanoma research:
Melanoma switches phenotypes to become metastatic and drug-resistant
Phenotype switching may be involved in changing the appearance of melanoma tumors by altering the number and type of protein receptors that dot the surface of the individual melanoma cells within a tumor. Identifying the phenotype that patients exhibit may help determine which patients are more likely to benefit from existing medications while also providing an opportunity to create new targeted therapies.
“We were able to demonstrate for the first time that different receptors within a single signaling pathway—in this case, the Wnt signaling pathway—can guide the phenotypic plasticity of tumor cells, and increased signaling of Wnt5A in particular can result in an increase in highly invasive tumor cells that are less sensitive to existing treatments for metastatic melanoma,” said Ashani Weeraratna, PhD, of The Wistar Institute in Philadelphia, Pennsylvania.
While melanoma accounts for less than 5% of all cases of skin cancer, it is the deadliest form of the disease, resulting in the majority of deaths related to skin cancer, according to the American Cancer Society. The 5-year survival rate for patients with metastatic melanoma is about 15% to 20%, and although new, targeted therapies designed to combat the disease based on a person's genetics have become available in recent years, some of these drugs are not effective in many patients, and many who do respond well to the drugs often eventually become resistant to them.
Weeraratna's team focused on Wnt5A, a Wnt signaling molecule that has been found in increased levels in metastatic melanomas. In order for Wnt5A to promote the phenotype switch from early in the tumor's formation to the time it becomes metastatic, the tyrosine kinase receptor ROR2 is required. When ROR2 is not present, Wnt5A is unable to promote tumor metastasis. The only other member of the family that has been identified is ROR1, and this research was done to determine what role ROR1 might play in the progression of melanoma.
The researchers were able to determine that ROR1 inhibited the invasion of melanoma cells, and ROR1 was targeted for degradation by Wnt5A and ROR2. When ROR1 was silenced, the researchers observed that there was an increased rate of invasion of melanoma cells both in vitro and in vivo.
In addition to laboratory studies in cells and mice, the researchers tested their hypotheses in a small cohort of patients. They found that seven out of nine patients who demonstrated less than a 33% clinical response to vemurafenib had a positive expression of Wnt5A, and only two of the remaining 15 patients who had a 38% or greater clinical response to vemurafenib exhibited any Wnt5A expression.
Additionally, in eight patients who had undergone BRAF inhibitor therapy, the levels of Wnt5A were much lower in tumor cells prior to therapy compared to cells that were tested for Wnt5A after those same patients had relapsed. The study was published in Cancer Discovery (2013; doi:10.1158/2159-8290.CD-13-0005).
New monoclonal antibody is a "source of hope" for patients with metastatic melanoma
Experimental drug selumetinib benefits patients with metastatic uveal melanoma
Drug-resistant melanoma and breast cancer treated with potential new drug
Metastatic Melanoma Responds to Vemurafenib
New treatment on horizon offers hope for metastatic melanoma patients
Further information is available by clicking here: 'Lyme Disease further information'